LISA TRACKER

Monitoring the treatment of patients treated by anti-TNFα

Anti-TNFαs are therapeutic treatments widely prescribed to treat more than 50,000 patients affected by various chronic inflammatory pathologies. They consist of biomarkers capable of binding TNFα and blocking the action of the TNFα that is responsible for the inflammatory state.

Infliximab, Adalimumab, and Etanercept are anti-TNFα biologics recommended for treating pathologies such as rheumatoid arthritis, Crohn’s disease, ankylosing spondylarthritis, and psoriasis . These biotherapies represent a cost of some €1 billion in France.

Whatever the anti-TNF-α, some authors have demonstrated the appearance of anti-drug neutralizing antibodies (ADAb = Anti-Drug Antibodies) among patients presenting therapeutic resistance (20% to 60% of treated patients). This presence of ADAb appears as a precursor to potential clinical deterioration (therapeutic escape).

The LISA TRACKER Premium kits are the first CE marked kits allowing simultaneous dosage of three parameters within three hours of reaction from a serum sample:

  • Circulating TNFα is one of the main markers involved in the inflammatory process. TNFα is a complex predictive marker that may lead to new areas of research.
  • Prescribed anti-TNF-α (Infliximab, Adalimumab, Etanercept, Certolizumab-pegol, golimumab) to optimize dosage consistent with the presence or absence of ADAb.
  • The presence of antibodies directed against the medication (ADAb), of which authors have reported the presence among patients experiencing loss of drug efficacy.

These kits allow clinicians to monitor the patient’s trough plasma levels of these three parameters over time. The combination of these three parameters allows them to anticipate, optimize, and better manage the patient’s treatment.

 

Brochure

Brochure LISA TRACKER

Brochure IMMUNO-TROL LISA TRACKER

Theranostic Era

Monitoring of Biothérapies

Publications

Publication list_LT_juin 2013

Synthèse Symposium Inflammation 2011

Synthèse Symposium SFR 2010

Multimedia

Biotherapies managemnet in IBDs
Interview Prof. Roblin
(Gastro-entérologue – CHU Saint Etienne)

Instructions for use

LTA001 LISA-TRACKER Premium Adalimumab

LTA002 LISA-TRACKER Adalimumab

LTA003 LISA-TRACKER anti-Adalimumab

LTA005 LISA-TRACKER Duo Adalimumab

LTB002 LISA-TRACKER Bevacizumab

LTB003 LISA-TRACKER anti-Bevacizumab

LTB005 LISA-TRACKER Duo Bevacizumab

LTC001 LISA-TRACKER Premium Certolizumab

LTC002 LISA-TRACKER Certolizumab

LTC003 LISA-TRACKER anti-Certolizumab

LTC005 LISA-TRACKER Duo Certolizumab

LTE001 LISA-TRACKER Premium Etanercept

LTE002 LISA-TRACKER Etanercept

LTE003 LISA-TRACKER anti-Etanercept

LTE005 LISA-TRACKER Duo Etanercept

LTG002 LISA-TRACKER Golimumab

LTG003 LISA-TRACKER anti-Golimumab

LTG005 LISA-TRACKER Duo Golimumab

LTI001 LISA-TRACKER Premium Infliximab

LTI002 LISA-TRACKER Infliximab

LTI003 LISA-TRACKER anti-Infliximab

LTI005 LISA-TRACKER Duo Infliximab

LTR002 LISA-TRACKER Rituximab

LTR003 LISA-TRACKER anti-Rituximab

LTR005 LISA-TRACKER Duo Rituximab

LTT002 LISA TRACKER Tocilizumab

LTT003 LISA TRACKER anti-Tocilizumab

LTT004 LISA-TRACKER TNFalpha

LTT005 LISA-TRACKER Duo Tocilizumab

LTTR002 LISA-TRACKER Trastuzumab

LTTR003 LISA-TRACKER anti-Trastuzumab

LTTR005 LISA-TRACKER Duo Trastuzumab

LTU002 LISA-TRACKER Ustekinumab

LTU003 LISA-TRACKER anti-Ustekinumab

LTU005 LISA-TRACKER Duo-Ustekinumab

LTI-002-PC-LTI-003-PC-LTA-002-PC-LTA-003-PC-IMMUNO-TROL LISA TRACKER